Suchergebnisse - "Michon, Ingrid"

PubPharm (35)

1

Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors

enthalten in: Journal of clinical pharmacology | 2024

von Chen, G. | Sun, K. | Michon, I. | +5

2

Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors

enthalten in: The Journal of Clinical Pharmacology | 2024

von Chen, G. | Sun, K. | Michon, I. | +5

3

USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF

enthalten in: Europäisches Patentamt | 2023

von SONG HENG | SUN KEFENG | CROUTHAMEL MATTHEW | +6

4

USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF

enthalten in: Europäisches Patentamt | 2023

von SONG HENG | SUN KEFENG | CROUTHAMEL MATTHEW | +6

5

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling

enthalten in: CPT: pharmacometrics & systems pharmacology | 2023

von Mulford, D. | Ramsden, D. | Zhang, L. | +5

6

Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling

enthalten in: CPT: Pharmacometrics & Systems Pharmacology | 2023

von Mulford, D. | Ramsden, D. | Zhang, L. | +5

7

Pilocarpine-Induced Effects on Salivary Secretion as a Pharmacological Biomarker for Cholinergic Parasympathetic Activation

enthalten in: Clinical pharmacology in drug development | 2022

von Treijtel, N. | Groenendaal-van de Meent, D. | Michon, I. | +5

8

Pilocarpine‐Induced Effects on Salivary Secretion as a Pharmacological Biomarker for Cholinergic Parasympathetic Activation

enthalten in: Clinical Pharmacology in Drug Development | 2022

von Treijtel, N. | Groenendaal‐van de Meent, D. | Michon, I. | +5

9

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

enthalten in: Pharmaceutics | 2020

von Kanacher, T. | Lindauer, A. | Mezzalana, E. | +5

10

Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels

enthalten in: Advances in therapy | 2020

von Takizawa, M. | Cerneus, D. | Michon, I. | +4